These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 38317504)

  • 21. Susoctocog Alfa: A Review in Acquired Haemophilia A.
    Burness CB; Scott LJ
    Drugs; 2016 May; 76(7):815-21. PubMed ID: 27098420
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Turoctocog alfa pegol provides effective management for major and minor surgical procedures in patients across all age groups with severe haemophilia A: Full data set from the pathfinder 3 and 5 phase III trials.
    Tosetto A; Neff A; Lentz SR; Santagostino E; Nemes L; Sathar J; Meijer K; Chowdary P; Shen C; Landorph A; Hampton K
    Haemophilia; 2020 May; 26(3):450-458. PubMed ID: 32293786
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Susoctocog-alfa (Obizur
    Zanon E; Pasca S; Borchiellini A; Lodigiani C; Molinari AC; Ambaglio C; Valeri F; Preti PS; Moscatelli P; Simioni P
    Blood Transfus; 2020 Jul; 18(4):312-321. PubMed ID: 32698943
    [TBL] [Abstract][Full Text] [Related]  

  • 24. First report on the safety and efficacy of an extended half-life glycoPEGylated recombinant FVIII for major surgery in severe haemophilia A.
    Hampton K; Chowdary P; Dunkley S; Ehrenforth S; Jacobsen L; Neff A; Santagostino E; Sathar J; Takedani H; Takemoto CM; Négrier C
    Haemophilia; 2017 Sep; 23(5):689-696. PubMed ID: 28470862
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and efficacy of turoctocog alfa (NovoEight®) during surgery in patients with haemophilia A: results from the multinational guardian™ clinical trials.
    Santagostino E; Lentz SR; Misgav M; Brand B; Chowdary P; Savic A; Kilinc Y; Amit Y; Amendola A; Solimeno LP; Saugstrup T; Matytsina I
    Haemophilia; 2015 Jan; 21(1):34-40. PubMed ID: 25273984
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Octocog alfa, antihaemophilic factor (recombinant), plasma/albumin free method (Advate®): a review of its use in the management of patients with haemophilia A.
    Dhillon S
    Drugs; 2012 May; 72(7):987-1007. PubMed ID: 22564135
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy.
    Lentz SR; Misgav M; Ozelo M; Salek SZ; Veljkovic D; Recht M; Cerqueira M; Tiede A; Brand B; Mancuso ME; Seremetis S; Lindblom A; Martinowitz U
    Haemophilia; 2013 Sep; 19(5):691-7. PubMed ID: 23647704
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SURgical interventions with FEIBA (SURF): international registry of surgery in haemophilia patients with inhibitory antibodies.
    Négrier C; Lienhart A; Numerof R; Stephens D; Wong WY; Baghaei F; Yee TT
    Haemophilia; 2013 May; 19(3):e143-50. PubMed ID: 23282031
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alternative therapies for the management of inhibitors.
    Shima M; Lillicrap D; Kruse-Jarres R
    Haemophilia; 2016 Jul; 22 Suppl 5():36-41. PubMed ID: 27405674
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recombinant porcine factor VIII for high-risk surgery in paediatric congenital haemophilia A with high-titre inhibitor.
    Croteau SE; Abajas YL; Wolberg AS; Nielsen BI; Marx GR; Baird CW; Neufeld EJ; Monahan PE
    Haemophilia; 2017 Mar; 23(2):e93-e98. PubMed ID: 28124406
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Continuous infusion of B-domain deleted recombinant factor VIII (ReFacto) in patients with haemophilia A undergoing surgery: clinical experience.
    Stieltjes N; Altisent C; Auerswald G; Négrier C; Pouzol P; Reynaud J; Roussel-Robert V; Savidge GF; Villar A; Schulman S
    Haemophilia; 2004 Sep; 10(5):452-8. PubMed ID: 15357770
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetic, efficacy and safety evaluation of B-domain-deleted recombinant FVIII (SCT800) for prophylactic treatment in adolescent and adult patients with severe haemophilia A.
    Xue F; Zhao X; Sun J; Zeng X; Yang F; Xu M; Yu Z; Gu W; Feng Y; Li W; Zheng C; Bi H; Xie L; Gai W; Yang R
    Haemophilia; 2021 Sep; 27(5):814-822. PubMed ID: 34089210
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neutralization of antifactor VIII inhibitors by recombinant porcine factor VIII.
    Barrow RT; Lollar P
    J Thromb Haemost; 2006 Oct; 4(10):2223-9. PubMed ID: 16856973
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Results of a randomized phase III/IV trial comparing intermittent bolus versus continuous infusion of antihaemophilic factor (recombinant) in adults with severe or moderately severe haemophilia A undergoing major orthopaedic surgery.
    Pabinger I; Mamonov V; Windyga J; Engl W; Doralt J; Tangada S; Spotts G; Ewenstein B
    Haemophilia; 2021 May; 27(3):e331-e339. PubMed ID: 33772963
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of a recombinant factor IX (Bax326) in previously treated patients with severe or moderately severe haemophilia B undergoing surgical or other invasive procedures: a prospective, open-label, uncontrolled, multicentre, phase III study.
    Windyga J; Lissitchkov T; Stasyshyn O; Mamonov V; Ghandehari H; Chapman M; Fritsch S; Wong WY; Pavlova BG; Abbuehl BE
    Haemophilia; 2014 Sep; 20(5):651-8. PubMed ID: 24697870
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recombinant porcine factor VIII corrects thrombin generation in vitro in plasma from patients with congenital hemophilia A and inhibitors.
    Négrier C; Oldenburg J; Kenet G; Meeks SL; Bordet JC; Müller J; Le Quellec S; Turecek PL; Tripkovic N; Dargaud Y
    Res Pract Thromb Haemost; 2022 May; 6(4):e12731. PubMed ID: 35765670
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expanding the ortholog approach for hemophilia treatment complicated by factor VIII inhibitors.
    Zakas PM; Vanijcharoenkarn K; Markovitz RC; Meeks SL; Doering CB
    J Thromb Haemost; 2015 Jan; 13(1):72-81. PubMed ID: 25315236
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and efficacy of turoctocog alfa in the prevention and treatment of bleeds in previously untreated paediatric patients with severe haemophilia A: Results from the guardian 4 multinational clinical trial.
    Yaish H; Matsushita T; Belhani M; Jiménez-Yuste V; Kavakli K; Korsholm L; Matytsina I; Philipp C; Reichwald K; Wu R
    Haemophilia; 2020 Jan; 26(1):64-72. PubMed ID: 31816159
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Zero incidence of factor VIII inhibitors and successful haemostatic response in previously factor VIII-treated patients with haemophilia A switching to turoctocog alfa in a noninterventional study.
    Escuriola Ettingshausen C; Katsarou O; Kotnik BF; Borel Derlon A; Schwarz R; Ypma PF; Matytsina I; Dey S; Schutgens REG
    Haemophilia; 2022 Jan; 28(1):46-54. PubMed ID: 34791736
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acquired haemophilia A, concomitant acute myocardial infarction and urgent major surgery: How to successfully treat a critical patient with rpFVIII (Obizur®).
    Zanon E; Pasca S; Spiezia L; Poletto F; Gherardi S; Simioni P
    Thromb Res; 2020 Nov; 195():125-127. PubMed ID: 32683151
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.